Related Experiment Video
Updated: Sep 20, 2025

Assessment of Gut Barrier Integrity in Mice Using Fluorescein-Isothiocyanate-Labeled Dextran
Published on: November 18, 2022
MSC Promotes the Secretion of Exosomal miR-34a-5p and Improve Intestinal Barrier Function Through METTL3-Mediated
Yi-Jun Li1, Qing-Wen Xu1, Cong-Hui Xu1
1Department of Gastrointestinal Surgery, Second Affiliated Hospital of Kunming Medical University, No.374, Dianmian Road, Kunming, 650101, Yunnan Province, People's Republic of China.
Abstract:
Intestinal ischemia/reperfusion (I/R) injury (IIRI) is associated with high prevalence and mortality rate. Recently, mesenchymal stem cell (MSC) therapy attracted more attentions. However, the function and regulatory mechanism of MSC-derived exosomal miRNAs during IIRI remain largely uninvestigated. The in vitro and in vivo IIRI models were established. MSC were characterized by immunofluorescent staining and flow cytometry. Purified exosomes were characterized by transmission electron microscopy (TEM), flow cytometry, and western blot. The expression of key molecules was detected by western blot and qRT-PCR. CCK-8, TUNEL, and transepithelial electrical resistance (TER) assays were employed to assess cell viability, apoptosis, and intestinal integrity, respectively. Pre-miR-34A m6 modification was evaluated by methylated RNA immunoprecipitation (MeRIP)-qPCR. RNA pull-down and RIP were used to validate the direct association between pre-miR-34A and IGF2BP3. MSC-derived exosomal miR-34a-5p alleviated OGD/R-induced injury. In addition, MSC ameliorated OGD/R-induced injury through METTL3 pathway. Mechanistic study revealed that miR-34a-5p was modulated by METTL3/IGF2BP3-mediated m6A modification in MSC. The in vitro and in vivo functional experiments revealed that MSC secreted exosomal miR-34a-5p and ameliorated IIRI through METTL3/IGF2BP3-mediated m6A modification of pre-miR-34A. MSC promoted the secretion of exosomal miR-34a-5p and improved intestinal barrier function through METTL3/IGF2BP3-mediated pre-miR-34A m6A modification.
Insights
Mesenchymal stem cells (MSCs) protect against intestinal ischemia/reperfusion injury (IIRI) by secreting exosomal miR-34a-5p. This microRNA
Area of Science:
- Gastroenterology
- Regenerative Medicine
- Molecular Biology
Background:
- Intestinal ischemia/reperfusion injury (IIRI) presents a significant clinical challenge with high mortality.
- Mesenchymal stem cell (MSC) therapy shows promise, but the mechanisms of MSC-derived exosomes in IIRI are not fully understood.
- Exosomal microRNAs (miRNAs) are crucial mediators, yet their role in MSC-based IIRI treatment requires investigation.
Purpose of the Study:
- To investigate the function and regulatory mechanism of MSC-derived exosomal miRNAs in intestinal ischemia/reperfusion injury (IIRI).
- To elucidate the role of miR-34a-5p and its regulatory pathway involving METTL3/IGF2BP3-mediated m6A modification in MSC-treated IIRI.
Main Methods:
- Established in vitro and in vivo models of intestinal ischemia/reperfusion injury (IIRI).
- Characterized mesenchymal stem cells (MSCs) and their derived exosomes using immunofluorescence, flow cytometry, TEM, and western blot.
- Assessed cell viability, apoptosis, and intestinal integrity using CCK-8, TUNEL, and TER assays; analyzed molecular mechanisms via qRT-PCR, western blot, MeRIP-qPCR, RNA pull-down, and RIP assays.
Main Results:
- MSC-derived exosomal miR-34a-5p significantly alleviated oxygen-glucose deprivation/reperfusion (OGD/R)-induced injury in vitro and in vivo.
- MSCs ameliorated IIRI by modulating the METTL3/IGF2BP3 pathway, which mediates m6A modification of pre-miR-34A.
- MSC treatment promoted the secretion of exosomal miR-34a-5p, enhancing intestinal barrier function.
Conclusions:
- MSC-derived exosomal miR-34a-5p is a key therapeutic factor in mitigating intestinal ischemia/reperfusion injury.
- The METTL3/IGF2BP3-mediated m6A modification of pre-miR-34a is a critical regulatory mechanism for exosome secretion and therapeutic efficacy.
- This study highlights a novel therapeutic strategy utilizing MSC-derived exosomes for treating IIRI.
Related Concept Videos
MicroRNAs
Renewal of Intestinal Stem Cells

